Document is current
Any future updates will be listed below
-
Authors
Kameda, Kazuaki https://orcid.org/0000-0001-8418-5118
Kako, Shinichi https://orcid.org/0000-0002-2635-3395
Kim, Sung-Won
Usui, Yoshiaki https://orcid.org/0000-0001-6180-0704
Kato, Koji
Fukuda, Takahiro
Uchida, Naoyuki https://orcid.org/0000-0001-5952-5926
Kobayashi, Hikaru
Wakayama, Toshio
Sakaida, Emiko https://orcid.org/0000-0002-7254-1928
Yano, Shingo https://orcid.org/0000-0002-5895-5382
Imada, Kazunori https://orcid.org/0000-0002-0945-0513
Nara, Miho
Ikeda, Takashi https://orcid.org/0000-0003-3976-5230
Fuchida, Shin-ichi
Ishikawa, Jun
Sugahara, Hiroyuki
Kanda, Junya https://orcid.org/0000-0002-6704-3633
Kimura, Takafumi
Ichinohe, Tatsuo https://orcid.org/0000-0002-0393-4066
Atsuta, Yoshiko https://orcid.org/0000-0003-4404-2870
Kondo, Eisei https://orcid.org/0000-0003-0995-9405
-
Funding
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (20J14747)
Jichi Medical University Graduate Student Research Award 2021; Japan Leukemia Research Award.
Japan Agency for Medical Research and Development (19ek0510023h)
- License Information
-
More Information
Article History
Received: 30 November 2021
Revised: 3 March 2022
Accepted: 10 March 2022
First Online: 28 March 2022
Competing interests
: Conflicts of interest disclosure: K. Kato is a consultant for, and has received research funding from AbbVie, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo, Eisai, and Novartis; is a consultant for AstraZeneca; has received honoraria and research funding from Bristol-Myers Squibb, Kyowa Kirin, and Ono; is a consultant and has received honoraria and research funding from Celgene, Janssen; has received honoraria from Sumitomo Dainippon Pharma Co., Ltd., NSD, Mundi, outside the submitted work. K.I. has received honoraria from Chugai Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Novartis Pharma K.K., Celgene Co., Ltd., Bristol-Myers Squibb K.K., Takeda Pharmaceutical Co. Ltd., Nippon Shinyaku Co., Ltd., Otuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., and Sumitomo Dainippon Pharma Co., Ltd., outside the submitted work. S.F. has received honoraria from Takeda Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Sanofi, Bristol-Myers Squibb Co., Ltd., and Celgene Co., Ltd., outside the submitted work. T.I. reports research funding from Astellas Pharma, Chugai Pharmaceutical Co., CSL Behring, Eisai Co., FUJIFILM Wako Chemicals., Kyowa Kirin Co., Ono Pharmaceutical Co., Pfizer, Nippon Shinyaku Co., Abbvie, Otsuka Pharmaceutical Co., Repertoire Genesis Inc., Sumitomo Dainippon Pharma Co., Taiho Pharmaceutical Co., Takara Bio Inc., Takeda Pharmaceutical Co., and Zenyaku Kogyo Co., honoraria from Bristol-Myers Squibb, Celgene, Janssen Pharmaceutical K.K., Kyowa Kirin Co., Takeda Pharmaceutical Co., CSL Behring, Astellas Pharma, Eisai Co., Novartis, FUJIFILM Wako Chemicals., Nippon Shinyaku Co., and Repertoire Genesis Inc., outside the submitted work. E.K. has received honoraria from Takeda Pharmaceutical Co and Sumitomo Dainippon Pharma Co, outside the submitted work. The remaining authors declare no competing financial interests.
